A total of 593 (44.6%) patients were not receiving any treatment for the management of facial angiofibroma or noted for systemic mTOR inhibitor use for facial angiofibroma or other TSC manifestations (Fig. 3). Here, MTOR is linked to Adenoma sebaceum.